Scarica l'app Stockscreener
2.165
4.59%
0.095
Vyome Holdings Inc Borsa (HIND) Ultime notizie
HIND Stock Price, Quote & Chart | VYOME HOLDINGS INC (NASDAQ:HIND) - ChartMill
HIND (Vyome Holdings) shares fall 2.86% despite Q4 2025 EPS beating analyst estimates by a wide 40% margin.Real Time Stock Idea Network - Newser
The next big opportunity lies in immune and rare disease white spaces: Venkat Nelabhotla, President & CEO, Vyome Holdings - Indian Pharma Post
The next big opportunity lies in immune and rare disease white spaces: Venkat Nelabhotla, President & CEO, Vyome Holdings, Inc. - Indian Pharma Post
Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026 - BioSpace
Vyome reports positive phase 2 results for cancer wound treatment By Investing.com - Investing.com Australia
Vyome reports positive phase 2 results for cancer wound treatment - Investing.com
HIND Financials: Income Statement, Balance Sheet & Cash Flow | Vyome Holdings, Inc. - Stock Titan
Vyome Holdings (HIND) Stock Consolidates (Eye on Rally) 2026-04-20Social Trading Insights - Xã Châu Thành
Vyome Holdings (HIND) Stock: Why Institutions Watch It (Ticks Lower) 2026-04-18Investment Community Signals - Cổng thông tin điện tử tỉnh Lào Cai
Vyome Holdings (STU:24O0) PB Ratio : 0.00 (As of Apr. 16, 2026) - GuruFocus
Vyome Holdings, Inc. (HIND) stock price, news, quote and history - Yahoo Finance UK
Breaking News about Vyome Holdings, Inc.Common Stock (Nasdaq:HIND) - FinancialContent
Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026 - BioSpace
Vyome to present VT-1953 Phase 2 data at cancer research meeting By Investing.com - Investing.com South Africa
Vyome to present VT-1953 Phase 2 data at cancer research meeting - Investing.com
HIND Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Vyome Holdings bolsters financial position to support VT-1953 pivotal study through 2027 - Indian Pharma Post
RSLS Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Vyome Holdings Inc (HIND) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... By GuruFocus - Investing.com Canada
HIND Technical Analysis & Stock Price Forecast - Intellectia AI
HIND Should I Buy - Intellectia AI
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase - Business Wire
Vyome Holdings, Inc.: Fundamental Analysis and Financial Ratings | H1O | US92943X1046 - marketscreener.com
Vyome Holdings Reports Positive Phase 2 Clinical Results for VT-1953 Topical Gel in Malignant Fungating Wounds and Acne Treatment – 2026 Company Overview and Pipeline Update - Minichart
Vyome Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Vyome 10-K: $0.32M Revenue, $(4.86) Loss per Share - TradingView
Vyome (HIND) versus Its Competitors Critical Analysis - Defense World
Head-To-Head Comparison: Vyome (HIND) versus The Competition - Defense World
Vyome (HIND) vs. Its Rivals Head to Head Contrast - Defense World
Vyome (HIND) & The Competition Head to Head Analysis - Defense World
Reviewing Vyome (HIND) and Its Rivals - Defense World
HIND Stock Rallies 70% Pre-Market Today – Find Out Why - Stocktwits
RSLS SEC FilingsReShape Lifesciences Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Vyome (HIND) versus Its Rivals Financial Analysis - Defense World
Analyzing Vyome (HIND) & Its Peers - Defense World
Vyome (HIND) & Its Peers Financial Survey - Defense World
Critical Comparison: Vyome (HIND) versus The Competition - Defense World
Financial Contrast: Vyome (HIND) & The Competition - Defense World
Vyome’s Livechain Acquires Humanyze to Expand AI HR Analytics - TipRanks
Vyome Holdings Unit LiveChain to Acquire $5.8M Humanyze Notes, Issuing 25% Equity to Remus - TradingView
Livechain Completes Acquisition of Senior, Secured Debt of Humanyze, An MIT Incubated, AI Enabled HR Analytics Company - 01net
Livechain completes acquisition of senior, secured debt of Humanyze - marketscreener.com
Reviewing Vyome (HIND) and The Competition - Defense World
Head to Head Review: Vyome (HIND) and Its Rivals - Defense World
Comparing Vyome (NASDAQ:HIND) and Nanovibronix (NASDAQ:FEED) - Defense World
Vyome Therapeutics2026 Latest Shareholding - Tracxn
Reviewing Vyome (HIND) & The Competition - Defense World
Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity - Bluefield Daily Telegraph
Critical Survey: Vyome (HIND) & Its Competitors - Defense World
Vyome (HIND) versus Its Competitors Financial Analysis - Defense World
Analyzing Vyome (HIND) & Its Competitors - Defense World
0.78%
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):